Bumblebees shouldn't be able to fly, and a company as large as Johnson & Johnson (NYSE:JNJ) shouldn't be able to post double digit gains. Somehow both seemingly impossible events continue to occur before our eyes. I can't explain the flight of the bumblebee, but Johnson & Johnson's ability to defy gravity is less of a mystery.
During the second quarter all segments posted year-on-year gains, but pharmaceuticals are this company's biggest growth engine. A string of successful drug launches make Johnson & Johnson look like the pharmaceutical industry's Cape Canaveral. Watch the slideshow below to find out what's driving growth at Johnson & Johnson.
Leaked: This coming blockbuster could make even Johnson & Johnson jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.